New Generation CAR T-Cells For Cancer Therapy

Feb 6, 2018
Author: 
Linda Quattrin

With CAR T-cell therapy one of the promising technologies emerging in targeted cancer treatment, University of Toronto scientists have taken a step forward in improving the potential effectiveness of this therapeutic approach.

Naoto Hirano - 1

In a paper published this week in Nature Medicine, U of T immunology professor Naoto Hirano – working with colleagues at University Health Network (UHN) and Takara Bio in Japan – outlines a novel method for production of these “living drugs”. The team’s new generation CAR T-cells multiply and remain viable as living cells over a longer period, and show greater effectiveness in fighting specific tumours in immune-deficient mice with human-derived cancer.

“We are hopeful that this technique can move forward with further study to improve the beneficial effects of CAR T-cell therapy for patients,” said Prof. Hirano, a hematologist and oncologist, who is an Associate Professor of Medicine in the Department of Immunology at U of T, and Senior Scientist at Princess Margaret Cancer Centre, UHN. “The benefits of this targeted cancer therapy are very promising, if we can refine our laboratory constructs to optimize their therapeutic effect and minimize any unexpected consequences.”

CAR T-cell therapy was approved by the U.S. Food and Drug Administration in 2017 for the treatment of certain leukemias and lymphomas. The approach involves taking T cells (a type of immune cell) from a patient’s blood and changing them in the laboratory to target that patient’s specific cancer cells. The lab adds a gene for a special receptor called a chimeric antigen receptor (CAR) into the T cells, then grows millions of those CAR T cells, which are then given to the patient by infusion.

While the treatment is very effective in killing specific cancer cells, some patients have experienced serious side effects, such as very high fevers and dangerously low blood pressure, especially as the CAR T-cells multiply in the body in the days after treatment. That’s why scientists are continuing to refine this powerful anti-tumour approach.

Prof. Hirano’s new-generation CAR design can be used in any CAR T-cell, independent of the specific tumour it targets. UHN has filed a patent application related to this study on which Prof. Hirano is the lead inventor. Funding for this research was provided by a number of sources, including the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research, BioCanRX Catalyst Program, the Princess Margaret Cancer Foundation and others. The study was partly sponsored by Takara Bio, Inc.

Feb
1 – 28
Black Futures: A Series of Programs Using the Lens of Afrofuturism to Explore and Present Arts, Dialogue and Well-Being
Other | 7:00am–9:00pm
Feb 19 Cinema Medica: Bending the Arc
Other | 6:00pm–9:00pm
Feb
20 – 23
Daffydil: The Musical
| 8:00pm–8:00pm
Feb 23 2019 BPAO Annual Health Symposium
Symposium | 8:15am
Feb
24 – 27
32nd Annual Update In Emergency Medicine
Conference | 6:30am–4:00pm
Feb 26 Regulatory Jurisdictions in Medical Devices
Workshop/Seminar | 5:00pm–7:00pm
Feb 28 – Mar 29
Leading Transformation: Building Adaptive Capacity - Advanced Learning Program at IHPME
Course | 8:30am–5:00pm

Tweets

UofT Medicine
@uoftmedicine
RT : Your Black Student Application Program ( BSAP) is really just amazing to promote diversity for physicians… https://t.co/hNZ1mDYiO9
UofT Medicine
@uoftmedicine
Prof is developing a compound to target brain receptors impaired with both aging & depression https://t.co/0EOF7ytx1P
UofT Medicine
@uoftmedicine
RT : is coming together! Get you're tickets now! And plot twist you'll see stage crew attemp… https://t.co/jBL4VVTD5I

UofTMed Magazine

Have we lost the art of dying?

Sign up for your free digital copy.
Back to Top